Dr. Hope Rugo is on our Scientific Advisory Board. This is part of her bio on our website:
Dr. Hope Rugo is the Director of the Breast Oncology Clinical Trials Program at UCSF. She is the principal investigator for multiple clinical trials studying novel targeted therapeutics combined with standard treatments to improve clinical results in early and late-stage breast cancer. She is also researching cognitive function in patients receiving chemotherapy for breast cancer as well as ways to reduce toxicity from therapy.
The 40th annual Miami Breast Cancer Conference just concluded and Dr. Rugo was Co-Chair. The article linked below quotes her.
https://www.medpagetoday.com/meetingcoverage/...ate_active
Antibody-drug conjugates (ADCs) have taken the field of breast cancer by storm and appear poised to expand their reach into earlier lines of therapy and early-stage disease, a breast cancer specialist said here.
ADCs offer an "exciting and effective drug delivery system" for multiple subtypes of metastatic breast cancer, and ongoing clinical trials are exploring whether the agents' benefits extend beyond the metastatic setting. The success of trastuzumab deruxtecan (T-DXd, Enhertu) and sacituzumab govitecan (Trodelvy) have helped spur development of more ADCs, some of which have begun phase III clinical evaluation, said Hope Rugo, MD, of the University of California San Francisco.
“Antibody-drug conjugates are an exciting and effective drug delivery system that have an established role in all of the [traditional] subsets plus a new subset of breast cancer in the metastatic setting," she said in closing. "There is a huge potential in early-stage disease, and I think that antibody-drug conjugates are likely to replace giving naked chemotherapy in the not-to-distant future. Toxicity management is critical as we treat our patients with these highly effective new drugs."
There was no mention of Leronlimab, perhaps due to lack of ongoing trials????
In any event, the following footnote was a little surprising:
Disclosures
Rugo disclosed relationships with AMBRX, Astellas, AstraZeneca, Daiichi Sankyo, F. Hoffmann-La Roche, Genentech, Gilead Sciences, GlaxoSmithKline, Merck, Novartis, OBI Pharma, Pfizer, Pionyr Immunotherapeutics, Seattle Genetics, Semonix, Taiho Oncology, Veru, Puma, NAPO, and Blueprint.
No mention of CytoDyn. Do we pay members of our scientific advisory board? Are they actively consulting with the company?
Dr. Hope Rugo is the Director of the Breast Oncology Clinical Trials Program at UCSF. She is the principal investigator for multiple clinical trials studying novel targeted therapeutics combined with standard treatments to improve clinical results in early and late-stage breast cancer. She is also researching cognitive function in patients receiving chemotherapy for breast cancer as well as ways to reduce toxicity from therapy.
The 40th annual Miami Breast Cancer Conference just concluded and Dr. Rugo was Co-Chair. The article linked below quotes her.
https://www.medpagetoday.com/meetingcoverage/...ate_active
Antibody-drug conjugates (ADCs) have taken the field of breast cancer by storm and appear poised to expand their reach into earlier lines of therapy and early-stage disease, a breast cancer specialist said here.
ADCs offer an "exciting and effective drug delivery system" for multiple subtypes of metastatic breast cancer, and ongoing clinical trials are exploring whether the agents' benefits extend beyond the metastatic setting. The success of trastuzumab deruxtecan (T-DXd, Enhertu) and sacituzumab govitecan (Trodelvy) have helped spur development of more ADCs, some of which have begun phase III clinical evaluation, said Hope Rugo, MD, of the University of California San Francisco.
“Antibody-drug conjugates are an exciting and effective drug delivery system that have an established role in all of the [traditional] subsets plus a new subset of breast cancer in the metastatic setting," she said in closing. "There is a huge potential in early-stage disease, and I think that antibody-drug conjugates are likely to replace giving naked chemotherapy in the not-to-distant future. Toxicity management is critical as we treat our patients with these highly effective new drugs."
There was no mention of Leronlimab, perhaps due to lack of ongoing trials????
In any event, the following footnote was a little surprising:
Disclosures
Rugo disclosed relationships with AMBRX, Astellas, AstraZeneca, Daiichi Sankyo, F. Hoffmann-La Roche, Genentech, Gilead Sciences, GlaxoSmithKline, Merck, Novartis, OBI Pharma, Pfizer, Pionyr Immunotherapeutics, Seattle Genetics, Semonix, Taiho Oncology, Veru, Puma, NAPO, and Blueprint.
No mention of CytoDyn. Do we pay members of our scientific advisory board? Are they actively consulting with the company?
10
